Long-term survey of survival time, histological transformation, and secondary malignancies in Japanese patients with advanced-stage follicular lymphoma in the rituximab era: Hokkaido Hematology Study Group
Long-term survey of survival time, histological transformation, and secondary malignancies in Japanese patients with advanced-stage follicular lymphoma in the rituximab era: Hokkaido Hematology Study Group
复制标题
利妥昔单抗时代日本晚期滤泡性淋巴瘤患者生存时间、组织学转化和继发性恶性肿瘤的长期调查：北海道血液学研究组
DOI：
10.1007/s12185-014-1629-4
复制
发表时间：
2014
期刊：
影响因子：
2.1
通讯作者：
Kato J
中科院分区：
文献类型：
--
作者：
Hirayama Y;Ishitani K;Ota S;Kurosawa M;Kondo T;Takimoto R;Mori A;Sakai H;Torimoto Y;Yamamoto S;Sato K;Iwasaki H;Kohda K;Ishida T;Kakinoki Y;Fukuhara T;Kato J
在引入利妥昔单抗后，晚期滤泡性淋巴瘤（FL）病例的长期总生存率（OS）预计将在引入利妥昔单抗后改善：但是，在此情况下，由于FL的发病率相对较低，亚洲缺乏大规模的调查数据。我们进行了一项回顾性调查，以评估新诊断的晚期FL患者的治疗结果，2001年1月至2010年12月，在北海道的29个机构中实施了FL阶段。患者总数为443例（男性47.6%，女性52.4%），中位年龄为55岁（范围20-80岁）。在检查的病例中，42.2%为III期，57.8%为IV期。此外，62.5%、19.7%、9.2%、5.2%和3.4%的性能状态分别为0、1、2、3和4。5年OS为91.2%，未观察到生存平台期。17例患者发生继发性恶性肿瘤（6例血液病和11例实体癌; 5年概率为4.2%）。18例患者发生转化（5年概率，4.5%）。转化治疗后5年的总生存率为50%。在引进利妥昔单抗之前，据报道日本晚期FL患者的5- 10年OS约为30- 60%。虽然这些数据有限，但在利妥昔单抗时代，在日本观察到OS改善。
Following the introduction of rituximab, the long-term overall survival (OS) rate of advanced-stage follicular lymphoma (FL) cases was expected to improve after the introduction of rituximab: however, there is a lack of large-scale survey data in Asia due to the relatively low incidence of FL. We conducted a retrospective survey to assess the treatment outcomes in patients with newly diagnosed advanced-stage FL in 29 institutions in Hokkaido from January 2001 to December 2010. The total number of patients was 443 (men 47.6 %, women 52.4 %), with a median age of 55 years (range 20–80 years). Of the cases examined, 42.2 % had stage III and 57.8 % had stage IV disease. Furthermore, 62.5, 19.7, 9.2, 5.2, and 3.4 % had performance statuses of 0, 1, 2, 3, and 4, respectively. The 5-year OS was 91.2 %, and no survival plateau was observed. Seventeen patients experienced secondary malignancies (six hematological diseases and 11 solid cancers; 5-year probability, 4.2 %). Eighteen patients experienced transformation (5-year probability, 4.5 %). The overall survival at 5 years after therapy for transformation was 50 %. Before the introduction of rituximab, the 5- to 10-year OS of advanced-stage FL patients in Japan was reported to be about 30–60 %. Although these data are limited, improvement in OS has been observed in Japan during the rituximab era.